<DOC>
	<DOC>NCT01017666</DOC>
	<brief_summary>The purpose of this study is to understand whether BIIB014 has potential to affect how certain drugs are broken down by the body.</brief_summary>
	<brief_title>BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam</brief_title>
	<detailed_description />
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine</mesh_term>
	<criteria>Healthy male or female subjects Between the ages of 18 and 45, inclusive. Must have a body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive Clinically significant abnormalities (as determined by the Investigator) Other unspecified reason that would make the subject unsuitable for enrollment (as determined by the Investigator)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Healthy Volunteer</keyword>
</DOC>